Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G P Sarna

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Cancer Treatment Reports|May 1, 1985
Phase II trial of alpha-lymphoblastoid interferon given weekly as treatment of advanced breast cancerG P Sarna, R A Figlin
Annals of Surgical Oncology|June 23, 2000
Adjuvant radiation trials for high-risk breast cancer patients: adequacy of lymphadenectomyA W Silberman, G P Sarna, D Palmer
Journal of Biological Response Modifiers|August 1, 1987
Phase II study of betaseron (beta ser17-interferon) as treatment of advanced malignant melanomaG P Sarna, R A Figlin, M Pertcheck
Journal of Biological Response Modifiers|February 1, 1989
Systemic administration of recombinant methionyl human interleukin-2 (Ala 125) to cancer patients: clinical resultsG P Sarna, R A Figlin, M Pertcheck, et al.
Cancer Treatment Reports|May 1, 1978
Chemo-immunotherapy for unresectable bronchogenic carcinomaG P Sarna, B B Lowitz, C M Haskell, et al.
Clinical and Experimental Immunology|June 1, 1992
Different lymphoid cell populations produce varied levels of neopterin, beta 2-microglobulin and soluble IL-2 receptor when stimulated with IL-2, interferon-gamma or tumour necrosis factor-alphaB Hofmann, H Bass, P Nishanian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1988
Recombinant interferon alfa-2a in metastatic renal cell carcinoma: assessment of antitumor activity and anti-interferon antibody formationR A Figlin, J B deKernion, E Mukamel, et al.
Journal of Biological Response Modifiers|February 1, 1990
A pilot study of intralymphatic interleukin-2. I. Cytotoxic and surface marker changes of peripheral blood lymphocytesH Shau, V Isacescu, Y Ibayashi, et al.
The American Journal of Medicine|December 1, 1981
High-dose combined-modality therapy and autologous bone marrow transplantation in resistant cancerD Douer, R E Champlin, W G Ho, et al.
Cancer|May 1, 1982
Veno-occlusive disease of the liver after high-dose mitomycin C therapy and autologous bone marrow transplantationH M Lazarus, M R Gottfried, R H Herzig, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Cancer Treatment Reports|May 1, 1985
Phase II trial of alpha-lymphoblastoid interferon given weekly as treatment of advanced breast cancerG P Sarna, R A Figlin
Annals of Surgical Oncology|June 23, 2000
Adjuvant radiation trials for high-risk breast cancer patients: adequacy of lymphadenectomyA W Silberman, G P Sarna, D Palmer
Journal of Biological Response Modifiers|August 1, 1987
Phase II study of betaseron (beta ser17-interferon) as treatment of advanced malignant melanomaG P Sarna, R A Figlin, M Pertcheck
Journal of Biological Response Modifiers|February 1, 1989
Systemic administration of recombinant methionyl human interleukin-2 (Ala 125) to cancer patients: clinical resultsG P Sarna, R A Figlin, M Pertcheck, et al.
Cancer Treatment Reports|May 1, 1978
Chemo-immunotherapy for unresectable bronchogenic carcinomaG P Sarna, B B Lowitz, C M Haskell, et al.
Clinical and Experimental Immunology|June 1, 1992
Different lymphoid cell populations produce varied levels of neopterin, beta 2-microglobulin and soluble IL-2 receptor when stimulated with IL-2, interferon-gamma or tumour necrosis factor-alphaB Hofmann, H Bass, P Nishanian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1988
Recombinant interferon alfa-2a in metastatic renal cell carcinoma: assessment of antitumor activity and anti-interferon antibody formationR A Figlin, J B deKernion, E Mukamel, et al.
Journal of Biological Response Modifiers|February 1, 1990
A pilot study of intralymphatic interleukin-2. I. Cytotoxic and surface marker changes of peripheral blood lymphocytesH Shau, V Isacescu, Y Ibayashi, et al.
The American Journal of Medicine|December 1, 1981
High-dose combined-modality therapy and autologous bone marrow transplantation in resistant cancerD Douer, R E Champlin, W G Ho, et al.
Cancer|May 1, 1982
Veno-occlusive disease of the liver after high-dose mitomycin C therapy and autologous bone marrow transplantationH M Lazarus, M R Gottfried, R H Herzig, et al.
Pageof 1